Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
复制标题
DOI：
10.1016/j.jmii.2018.09.005
复制
发表时间：
2020-08-01
影响因子：
7.4
通讯作者：
Liu, Chun-Jen
中科院分区：
文献类型：
--
作者：
Hong, Chun-Ming;Liu, Chen-Hua;Liu, Chun-Jen
背景/目的：自直接作用抗病毒药物（DAA）问世以来，慢性丙型肝炎（CHC）的治疗进入了一个新时代。大量临床试验表明，DAA的治疗反应和耐受性优于聚乙二醇干扰素和利巴韦林的常规治疗，具有上级效果。然而，临床试验的结果可能不会直接应用于现实世界的实践。因此，我们的研究试图探讨各种DAA方案在台湾慢性丙型肝炎患者的有效性。方法：我们进行了一项回顾性研究，对400例慢性丙型肝炎患者。主要终点是检测不到HCV RNA（HCV RNA水平为
Background/purpose: Treatment of chronic hepatitis C (CHC) has entered a new era since the introduction of direct-acting antiviral agents (DAAs). Numerous clinical trials have shown that treatment response as well as tolerability of DAAs are superior to those of conventional therapy with pegylated interferon and ribavirin. However, the results of clinical trials may not be directly applied to real-world practice. Therefore our study tried to investigate the effectiveness of various DAA regimens in Taiwanese patients with chronic hepatitis C.Methods: We performed a retrospective study on 400 CHC patients. The primary endpoint was undetectable HCV RNA (an HCV RNA level of